← All research

"Ozempic Face" and Loose Skin: 10 Questions About Skin on a GLP-1

Last verified May 2026 · 10 questions · 16 PubMed citations

Questions taken from r/Zepbound, r/Wegovy, r/Semaglutide, r/Mounjaro

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed

The useful frame for this whole page is that skin is playing catch-up. Fat comes off in months; collagen and elastin remodel over months to years, and the gap between those two timescales is what people are seeing in the mirror. ★ That is why the post-bariatric literature is the best guide — it describes the same magnitude of loss, studied for far longer. ⚠ Where a treatment is popular but weakly evidenced we say so, and where the only reliable answer is surgical we say that too rather than offering a cream. ⛔ None of this is cosmetic vanity to be dismissed; skin changes are a common reason people stop an effective drug, which is why the last answer is about whether stopping actually helps.

Questions and answers

Q1.What is "Ozempic face", really?

★ It is fat-pad volume loss in the face, and it is not specific to this drug or even to drugs. The same hollowing follows any large, fast weight loss — bariatric surgery and severe caloric restriction included. ⚠ A 2024 systematic review of facial soft-tissue change after massive weight loss documented the cheek, temple, under-eye and under-chin compartments losing volume in proportion to total weight lost, with much the same pattern whether the loss came from surgery or medication. ★ So the name is misleading in a way that matters: nothing is happening to your face that would not happen at the same weight loss by any other route. A 2025 analysis of search trends found interest in facial volume restoration rising in step with prescribing volume, which suggests people are noticing something anatomically real rather than imagining it. ⛔ It also means the fix is not switching drugs. It is the rate of loss, and what you do about the volume.

PMID 39346804PMID 41255744PMID 33567185PMID 35658024

Q2.Is the loose skin permanent?

⚠ Partly, and how much depends on how much you lost, how quickly, your age and where your skin elasticity started. Bariatric surgery patients are the honest comparison group here, having lost as much and been followed for far longer. ★ A 2024 histological study comparing post-bariatric patients against other weight-loss patients found that large losses measurably rearrange how collagen and elastin sit in the dermis, and that the elasticity lost does not simply come back on its own. That last clause is the hard part. ⛔ Reviewing body contouring after bariatric surgery in 2022, researchers found spare skin to be the norm rather than a complication — especially past about 50 pounds — with nothing short of cutting it away carrying good evidence for substantial improvement. ★ Which does not mean nothing helps. It means creams and devices are managing appearance, not restoring elasticity, and should be priced accordingly.

PMID 38277086PMID 35893406PMID 42162206

Q3.Does losing weight slower help?

★ Probably, though nobody has run fast-versus-slow escalation as a trial with skin as the endpoint — so this is mechanism plus consistent observation rather than a result. ⚠ The logic holds across dermatology and plastic surgery: skin remodels through collagen and elastin turnover on a months-to-years timescale. When fat disappears faster than the dermis can reorganize, you are left with an envelope larger than what it now contains. ★ In the 2024 histological work, nothing predicted disorganized dermal tissue better than how much came off and how fast, and a 2026 review of skin quality on these drugs landed in the same place for medically driven loss: the quicker it goes, the more laxity shows. ⛔ So the lever is real — hold a dose longer, or settle below the maximum. ⚠ And so is the cost: slower loss means less total loss over the same period. That is a trade to make deliberately.

PMID 38277086PMID 42162206PMID 33567185PMID 35658024

Q4.Will I get new stretch marks?

★ Not from the drug — from the speed of the size change. Striae form when the dermal matrix cannot keep up with mechanical strain as tissue underneath expands or contracts quickly, which is why they show up in pregnancy, in puberty, and in both rapid gain and rapid loss regardless of cause. ⚠ A 2026 review of skin quality on these drugs found that where striae turned up, they followed how fast weight was moving rather than which molecule someone had taken. ★ There is a second effect worth knowing, because it causes unnecessary alarm: stretch marks you already had can become more visible as the fat beneath them thins, even when nothing new has formed. ⛔ On treatment, the cosmetic dermatology literature finds modest benefit from topical tretinoin and from laser for early red striae, with returns falling sharply once they have matured to pale silver.

PMID 42162206PMID 33934473PMID 30130428

Q5.Why is my skin so dry?

⚠ Several mechanisms are plausible and the evidence does not settle which dominates for any individual — so treat the following as candidates rather than a diagnosis. ★ The most actionable is fluid: thirst cues get blunted alongside hunger cues, so many people are simply drinking less without registering it. ★ The second is intake — eating substantially less lowers the fat-soluble vitamins and essential fatty acids that the skin barrier depends on. ⚠ A 2026 review of skin quality on these drugs recorded dryness and reduced hydration recurring across case series, proposing reduced subcutaneous fat volume, altered sebum production and lower overall nutritional intake as contributors. ⛔ The practical order matters: fix fluid and dietary fat before spending money on products, because a barrier short of its raw materials will not be rescued from the outside. ★ Bland emollients applied to damp skin are the cheap, evidenced step after that.

PMID 42162206PMID 41781778

Q6.Do fillers fix it?

⚠ They restore the look, not the cause — and knowing which you are buying matters. The underlying problem is loss of structural fat in the cheek, temple and under-eye compartments; the 2024 systematic review found volume loss dominant, with skin laxity secondary. Filler replaces volume. It does nothing about elasticity. ★ Reported approaches include hyperdilute calcium hydroxylapatite used to preserve facial volume during rapid loss, and poly-L-lactic acid as a collagen stimulator, though the published support is case-series-level rather than randomized. ⛔ Be aware of the timing trap: filling while you are still losing weight means chasing a moving target, and the volume you replace today sits against a face that will keep changing. ★ Most practitioners prefer to wait for weight stability for the same reason surgeons do. ⚠ A 2025 search-trends analysis confirms demand is rising fast — which is a reason for more skepticism about marketing claims, not less.

PMID 39346804PMID 41255744PMID 41127050PMID 40580932

Q7.When can I consider surgery for loose skin?

★ Once your weight has been stable for at least six to twelve months — that is the standard across post-bariatric body contouring, and it carries over directly. ⚠ The reasoning is mechanical in both directions. Keep losing after surgery and you generate new redundant skin the excision never accounted for. Regain, and you stretch the closure and compromise the result. Either way the operation you paid for stops fitting the body it was designed around. ★ Reviewers of contouring after bariatric surgery treat a settled weight as something you need before surgery is worth doing at all, not as a nicety. ⛔ Which has an implication people miss: if you intend to stay on a GLP-1 long-term, stable ON the drug is the relevant stability — you do not need to stop first, you need to stop changing. ★ The common procedures after large losses are abdominoplasty, arm lift, thigh lift and mastopexy. Clot prevention is a real consideration in this population and worth raising.

PMID 35893406PMID 36256762PMID 34268591PMID 26132939

Q8.Can training and protein prevent it?

⚠ Not prevent — but you can change what the result looks like, which is a more useful goal than it sounds. ★ The mechanism is about what fills the envelope. Weight loss on these drugs takes a meaningful share from lean tissue: STEP-1 averaged 14.9% loss with a notable lean component, and SURMOUNT-1 reached 20.9% at the top dose with the same concern. Muscle you keep occupies space under the skin; muscle you lose leaves the envelope emptier and the result more hollow, most visibly in the arms, thighs and abdomen. ★ The countermeasures are the bariatric standards and they are cheap: 1.2-1.6 g of protein per kg daily, each major muscle group trained two or three times a week, compound lifts first. ⛔ None of this restores elasticity that has already changed. It changes the ratio of what is underneath, which is the part still within your control.

PMID 33567185PMID 35658024PMID 38277086PMID 42162206

Q9.Are the under-eye changes real?

★ Real, documented, and now catching up with the forum discussion. A 2025 review catalogued periorbital and ocular-surface changes linked to this drug class, including hollowing of the upper eyelid sulcus, a more prominent tear trough, and altered skin quality around the eyes. ⚠ The mechanism is the same volume loss driving the rest of the facial change: the fat compartments around the eye thin as body fat falls. ★ The reason it can look simultaneously hollow AND puffy — which sounds contradictory and is the thing people find hardest to describe — is that hollowing above makes the lower lid fat pads more prominent by contrast, showing through thinner skin. Both appearances come from the same thinning. ⚠ A 2026 skin-quality review documented similar periorbital findings. ⛔ Ocular surface symptoms belong with an eye doctor rather than a dermatologist, and are not something to manage cosmetically.

PMID 41464694PMID 42162206

Q10.Should I stop the drug over this?

⚠ Rarely the most informed choice, and it often does not deliver what people expect. ★ Both the 2026 skin-quality review and the 2024 facial soft-tissue review landed in the same place: laxity, volume loss, dryness and striae follow from losing weight fast, not from the medication poisoning anything. Stopping does not undo the cause; it changes the direction of travel. ⛔ Regain will refill some volume — that part is true — but it brings the metabolic and psychological costs back with it, and the elasticity that has already changed stays changed. You can end up with the weight back and the skin unchanged. ★ The middle-ground moves clinicians actually use: lengthen the interval between dose increases to slow the rate, hold below the maximum, get protein and resistance training in place, and reassess once weight is stable. ⚠ If the distress is significant, that is worth saying out loud to your prescriber rather than quietly stopping.

PMID 42162206PMID 39346804PMID 26132939

References

  1. 1.Wilding JPH, Batterham RL, Calanna S, et al Once-Weekly Semaglutide in Adults with Overweight or Obesity N Engl J Med. 2021. PMID: 33567185.
  2. 2.Jastreboff AM, Aronne LJ, Ahmad NN, et al Tirzepatide Once Weekly for the Treatment of Obesity N Engl J Med. 2022. PMID: 35658024.
  3. 3.Pi-Sunyer X, Astrup A, Fujioka K, et al A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management N Engl J Med. 2015. PMID: 26132939.
  4. 4.Barone M, Brunetti B, D'Emilio R, et al Effects of GLP-1 Receptor Agonists on Skin Quality: A Comprehensive Literature Review Aesthetic Plast Surg. 2026. PMID: 42162206.
  5. 5.Jafar AB, Jacob J, Kao WK, et al Soft Tissue Facial Changes Following Massive Weight Loss Secondary to Medical and Surgical Bariatric Interventions: A Systematic Review Aesthet Surg J Open Forum. 2024. PMID: 39346804.
  6. 6.Mnajjed L, Mims MM Interest in Facial Volume Restorative Procedures With the Rise in "Ozempic Face": A Google Trends Analysis Plast Reconstr Surg Glob Open. 2025. PMID: 41255744.
  7. 7.Durairaj KK, McCarthy AD, Yambao M, et al Hyperdilute Radiesse Preserves Facial Volume in Glucagon-Like Peptide-1 Receptor Agonist Users Undergoing Rapid Weight Loss Aesthet Surg J Open Forum. 2025. PMID: 41127050.
  8. 8.Kapantais D, Tsoutsanis P Functional and Aesthetic Periorbital, Ocular Adnexal and Ocular Surface Changes Linked to GLP-1 Receptor Agonists J Clin Med. 2025. PMID: 41464694.
  9. 9.Moradi A, Kim JH, Kim JM, et al Clinical Efficacy of a Flavo-Proxylane Topical Regimen Pre- and Post-ultrasound Procedure for Subjects Undergoing Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Therapy Dermatol Ther (Heidelb). 2026. PMID: 41781778.
  10. 10.Haykal D, Haddad A, Cartier H, et al Poly-L-Lactic Acid in Aesthetic Dermatology: A Decade Beyond Volume Restoration Toward Regenerative Biostimulation Aesthet Surg J. 2025. PMID: 40580932.
  11. 11.Hany M, Zidan A, Ghozlan NA, et al Comparison of Histological Skin Changes After Massive Weight Loss in Post-bariatric and Non-bariatric Patients Obes Surg. 2024. PMID: 38277086.
  12. 12.Sadeghi P, Duarte-Bateman D, Ma W, et al Post-Bariatric Plastic Surgery: Abdominoplasty, the State of the Art in Body Contouring J Clin Med. 2022. PMID: 35893406.
  13. 13.Szymanski KD, Sequeira Campos MB Brachioplasty StatPearls. 2026. PMID: 36256762.
  14. 14.Petersen ML, Vázquez FJ, Mayer HF Mechanical Thromboprophylaxis Alone in Body Contouring Surgery for Post Massive Weight Loss Patients: Is this Good Enough? Aesthetic Plast Surg. 2022. PMID: 34268591.
  15. 15.Cantelli M, Camela E, Marasca C, et al Topical oil formulation of plant extracts and vitamins as effective treatment for stretch marks and xerosis-An observational longitudinal study J Cosmet Dermatol. 2021. PMID: 33934473.
  16. 16.Mazzella C, Cantelli M, Nappa P, et al Confocal microscopy can assess the efficacy of combined microneedling and skinbooster for striae rubrae J Cosmet Laser Ther. 2019. PMID: 30130428.

Questions are paraphrased from public forum threads and linked to their source where one was recorded. Answers summarize published trial data and FDA labeling. This is not medical advice, and no part of it replaces the judgment of whoever prescribes for you.